Hugo ten Cate


Prof. Hugo ten Cate graduated in Medicine at the University of Amsterdam in 1987. The title of his PhD thesis was 'Clinical and experimental studies with a low molecular weight heparinoid'. Hugo had his post-doctoral training at the laboratory of Prof. Robert Rosenberg and Dr Kenneth Bauer at the Beth Israel Hospital and Harvard Medical School Boston on mechanisms of inflammation associated coagulation activity (1988-1990). He completed his internal medicine training in 1996 and became a general internist in conjunction with research at Academic Medical Center (laboratory of Experimental Internal medicine, Prof. Pieter Reitsma). He received a Clinical Established Investigator grant from the Dutch Heart Foundation in 1998.

In 2002, Hugo ten Cate was appointed Professor of Clinical Thrombosis and Haemostasis at CARIM. In addition, Prof. ten Cate was appointed adjunct professor at the Center for Thrombosis and Haemostasis (CTH) at Gutenberg University Medical Center, Mainz, Germany in 2017

Since the transfer to CARIM in 2002 his research focus shifted from coagulation-inflammation research in sepsis models, to the broader field of cardiovascular (CV) disease (atherothrombosis and 'thrombo-inflammation'). A specific focus of current research is the pleiotropic actions of coagulation proteases in atherosclerosis, atherothrombosis and ischemia reperfusion injury. Clinical research is aimed at chronic thrombotic disease including peripheral artery disease, high risk patients with coronary disease on antithrombotic medication and, together with Dr Arina ten Cate-Hoek, on venous thrombosis and post thrombotic syndrome (PTS). He is workpackage leader in CVON consortia RACE-5 (coagulation and its impact on atrial fibrillation) and CONTRAST (acute ischemic stroke) and involved in the ITN consortia TAPAS and TICARDIO. His group has an ongoing target finding programme with Bayer (steered from CARIM by Dr Henri Spronk and Prof. Hugo ten Cate) as well as with 2M (on POC development).

Department of Biochemistry
Department of Internal Medicine
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 4.344
T: +31(0)43 388 42 62

  • 2022
    • De Simone, I., Baaten, C. C. F. M. J., Jandrot-Perrus, M., Gibbins, J. M., Ten Cate, H., Heemskerk, J. W. M., Jones, C. I., & van der Meijden, P. E. J. (2022). Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1. International journal of molecular sciences, 23(18), [10203].
    • Willems, L. H., Maas, D. P. M. S. M., Kramers, K., Reijnen, M. M. P. J., Riksen, N. P., Ten Cate, H., van der Vijver-Coppen, R. J., de Borst, G. J., Mees, B. M. E., Zeebregts, C. J., Hannink, G., & Warlé, M. C. (2022). Correction to: Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs, 82(13), 1435-1435.
    • Camm, C. F., Virdone, S., Goto, S., Bassand, J. P., van Eickels, M., Haas, S., Gersh, B. J., Pieper, K., Fox, K. A. A., Misselwitz, F., Turpie, A. G. G., Goldhaber, S. Z., Verheugt, F., Camm, J., Kayani, G., Panchenko, E., Oh, S., Luciardi, H. L., Sawhney, J. P. S., ... GARFIELD-AF Investigators (2022). Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF. Open Heart, 9(2), [e002038].
    • Falanga, A., Leader, A., Ambaglio, C., Bagoly, Z., Castaman, G., Elalamy, I., Lecumberri, R., Niessner, A., Pabinger, I., Szmit, S., Trinchero, A., Ten Cate, H., & Rocca, B. (2022). EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. HemaSphere, 6(8), e750.
    • de Laat, B., Stragier, H., de Laat-Kremers, R., Ninivaggi, M., Mesotten, D., Thiessen, S., Van Pelt, K., Roest, M., Penders, J., Vanelderen, P., Huskens, D., De Jongh, R., Vander Laenen, M., Fivez, T., ten Cate, H., Heylen, R., Heylen, L., & Steensels, D. (2022). Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S. Frontiers in cardiovascular medicine, 9, [966028].
    • Nagy, M., & ten Cate, H. (2022). What to expect from drug targeting factor XI?Cardiovascular Research, 118(10), E72-E74.
    • Carlo, A., Yan, Q., Ten Cate, H., De Laat-Kremers, R., De Laat, B., & Ninivaggi, M. (2022). Semi-automated thrombin dynamics applying the ST Genesia thrombin generation assay. Frontiers in cardiovascular medicine, 9, [912433].
    • Arnoldussen, C. W. K. P., Notten, P., Brans, R., Vroegindeweij, D., Tick, L. W., van de Poel, M. H. W., Wikkeling, O. R. M., Vleming, L. J., Koster, A., Jie, K. S. G., Jacobs, E. M. G., Planken, N., Wittens, C. H. A., ten Cate, H., Wildberger, J. E., & ten Cate-Hoek, A. J. (2022). Clinical impact of assessing thrombus age using magnetic resonance venography prior to catheter-directed thrombolysis. European Radiology, 32(7), 4555-4564.
    • Gorog, D. A., Storey, R. F., Gurbel, P. A., Tantry, U. S., Berger, J. S., Chan, M. Y., Duerschmied, D., Smyth, S. S., Parker, W. A. E., Ajjan, R. A., Vilahur, G., Badimon, L., ten Berg, J. M., ten Cate, H., Peyvandi, F., Wang, T. T., & Becker, R. C. (2022). Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 19(7), 475-495.
    • Aarnink, E. W., Huijboom, M. F. M., Bor, W. L., Maarse, M., Zheng, K. L., Ten Cate, H., Ten Berg, J. M., & Boersma, L. V. A. (2022). Hemostatic biomarkers and antithrombotic strategy in percutaneous left atrial interventions: State-of-the-art review. Thrombosis Research, 215, 41-51.